|
|
|
|
| LEADER |
03107nmm a2200277 u 4500 |
| 001 |
EB000618159 |
| 003 |
EBX01000000000000000471241 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781461204756
|
| 100 |
1 |
|
|a Moss, Richard B.
|
| 245 |
0 |
0 |
|a Cystic Fibrosis
|h Elektronische Ressource
|b Infection, Immunopathology, and Host Response
|c by Richard B. Moss
|
| 250 |
|
|
|a 1st ed. 1990
|
| 260 |
|
|
|a Totowa, NJ
|b Humana
|c 1990, 1990
|
| 300 |
|
|
|a XI, 251 p
|b online resource
|
| 505 |
0 |
|
|a Basic Aspects of Cystic Fibrosis -- The Relationship Between Atopy and Cystic Fibrosis -- Infection and Immunity to Pseudomonas -- Infection and Immunity to Staphylococcus aureus and Haemophilus influenzae -- The Impact of Respiratory Viral Infections in Patients with Cystic Fibrosis -- Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis -- Inflammation in the Lung in Cystic Fibrosis: A Vicious Cycle That Does More Harm Than Good? -- Upper Respiratory Disease, Sinusitis, and Polyposis -- Airway Reactivity in Cystic Fibrosis -- Pharmacokinetics of Drugs in Cystic Fibrosis -- Drug Allergy in Cystic Fibrosis -- Heart-Lung and Lung Transplantation for Cystic Fibrosis
|
| 653 |
|
|
|a Allergy
|
| 653 |
|
|
|a Allergology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Allergy and Immunology, Clinical and Experimental Progress
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4612-0475-6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4612-0475-6?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.97
|
| 520 |
|
|
|a This work is concerned with Cystic Fibrosis (CF), the most common fatal genetic disease in the Caucasian population. The decade of the 1980s was one of spectacular progress in understanding the genetic and molecu lar basis of CF. The research breakthroughs of the decade began with the first fundamental insights, published in 1981-1983, into the basic cellular pathophysiology of CF with demonstrations of altered ion transport in spe cialized exocrine epithelial tissues (1-3). Research progress shifted into a triumph of "reverse genetics," using restriction-fragment-Iength polymor phism DNA technology (4), with the localization of the CF gene to a region of chromosome 7 (5-7). Understanding, accelerated by an explOSion of in vitro methodologies for epithelial cell culture and transformation, allowed and physiological studies (8-11); these focused, controlled biochemical with increasing precision, on the molecular pathology of distal steps in the regulatory pathways for epithelial ion transport (12-19). Finally, the "end of the beginning" occurred in late 1989 with one of the great achievements of molecular genetics, the isolation and cloning of the CF gene (20). As a result, we now have a CF gene product, the cystic fibrosis transmembrane regulator (CFfR), possessing predicted amino acid sequence, suggested tertiary structure, and possible transmembrane transport function (21). These amazing developments have set the stage for the next round of advances, which surely will include: 1
|